Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Molecular Analysis for Precision Oncology Congress 2023

Start date: 04 Oct 2023
End date: 06 Oct 2023
Location: Paris, France

The Molecular Analysis for Precision Oncology Congress (MAP) 2023 took place from 4 to 6 October 2023 in Paris, France.

MAP is a congress designed to provide the latest data in the field of precision oncology, molecular profiling and personalised medicine.

The focus of the event is to create a bridge between basic scientists, or people working on new technologies, and medical doctors and healthcare providers.

Our globally recognised experts in clinical and precision oncology welcomed delegates for three days of discussions on the latest discoveries in precision medicine, cancer-stromal interactions, clonal evolution, metastatic dissemination and drug response and resistance.

The MAP Congress is the result of a solid partnership among Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer, all committed to offering the best care to people with cancer worldwide, through oncology education and research.

The partner societies had the pleasure of introducing a special day on 6 October 2023: “RoadMAP to the Clinic 2023: From organ specific to biomarker driven drug development and approval”. Society experts and stakeholders from the scientific community, regulatory and HTA authorities, patient advocates, methodological experts and pharmaceutical industry representatives participated in sessions comprising lectures and brainstorming discussion on this year’s theme ”How to transform development and registration of precision therapeutics in oncology from organ-specific to histology-agnostic and biomarker driven approvals”, in order to achieve molecularly informed, resource-rational and timely enrichment of the therapeutic armamentarium for our patients.